Article Content

CDC guidelines recommend ceftriaxone monotherapy for gonorrhea. The Centers for Disease Control and Prevention (CDC) no longer recommends dual therapy for the treatment of uncomplicated gonorrhea. As noted in the December 18, 2020, Morbidity and Mortality Weekly Report, the new recommendation calls for a single 500-mg intramuscular injection of ceftriaxone. If coinfection with chlamydia trachomatis cannot be excluded, patients should also receive 100 mg of oral doxycycline twice daily for seven days. Previously, the CDC recommended combination therapy to cotreat gonorrhea and possible chlamydia, beginning in 1985 with fluoroquinolones, followed in 2007 by cephalosporins, and, since 2012, with ceftriaxone and azithromycin. As part of ongoing antimicrobial stewardship, the CDC conducted a review of the literature and found that Neisseria gonorrhoeae is highly susceptible to ceftriaxone, while microbial resistance to azithromycin is increasing.